Introduction. Individuals from older populations tend to have more than 1 health condition (multimorbidity). Current approaches to produce economic evidence for clinical guidelines using decision-analytic models typically use a single-disease approach, which may not appropriately reflect the competing risks within a population with multimorbidity. This study aims to demonstrate a proof-of-concept method of modeling multiple conditions in a single decision-analytic model to estimate the impact of multimorbidity on the cost-effectiveness of interventions. Methods. Multiple conditions were modeled within a single decision-analytic model by linking multiple single-disease models. Individual discrete event simulation models were developed to evaluate the cost-effectiveness of preventative interventions for a case study assuming a UK National Health Service perspective. The case study used 3 diseases (heart disease, Alzheimer's disease, and osteoporosis) that were combined within a single linked model. The linked model, with and without correlations between diseases incorporated, simulated the general population aged 45 years and older to compare results in terms of lifetime costs and quality-adjusted life-years (QALYs). Results. The estimated incremental costs and QALYs for health care interventions differed when 3 diseases were modeled simultaneously (£840; 0.234 QALYs) compared with aggregated results from 3 single-disease models (£408; 0.280QALYs). With correlations between diseases additionally incorporated, both absolute and incremental costs and QALY estimates changed in different directions, suggesting that the inclusion of correlations can alter model results. Discussion. Linking multiple single-disease models provides a methodological option for decision analysts who undertake research on populations with multimorbidity. It also has potential for wider applications in informing decisions on commissioning of health care services and long-term priority setting across diseases and health care programs through providing potentially more accurate estimations of the relative cost-effectiveness of interventions.
associated with increased health care costs, service use, mortality, and reduced quality of life than is the case for those of single conditions. 3, 8, 9 Some commentators have suggested the need to focus on the prevention and management of multimorbidity rather than of single diseases. 10 Despite the resource and health implications of multimorbidity, most economic evaluations are conceptualized and designed to evaluate the incremental costs and benefits (relative cost-effectiveness) of interventions for single diseases 11 to recommend care and management for people with specific conditions. Decision-analytic models used to inform the clinical guidelines published by the National Institute for Health and Care Excellence (NICE) in England, and more widely, 12-14 seldom consider people with multiple conditions. 15 Economic evidence for clinical guideline development is informed by a decision-analytic model (hereafter ''economic model'') designed to appraise interventions to treat or manage adverse health events that are most likely to occur within the same (single) disease. 16 Consideration of multimorbidity in an economic model should potentially provide more reliable estimates than those from a single-disease approach. Consequently, taking account of multimorbidity should lead to improved decisions on adoption and implementation of interventions for populations with more than 1 condition. Taking account of multimorbidity in a single model is likely to change the estimates of costs and quality-adjusted lifeyears (QALYs) of treating and managing the diseases when compared with modeling separate multiple populations with single conditions. 17 Intuitively, the results from 2 or more separate disease models can be combined to obtain an understanding of the overall outcomes for a multimorbid population. However, combining recommendations produced for single conditions to take account of multimorbidity may not represent the clinically optimal or cost-effective use of health care resources without jointly accounting for the benefits and risks of interventions. 10, 18 Such an approach does not incorporate competing risks of death, nor does it account for the modification in the risks and health-related quality of life (HRQoL) of the population with multimorbidity.
This study aimed to present a proof-of-concept approach to taking account of multimorbidity in an economic model to generate robust estimates of incremental costs and health outcomes. The main focus was to present a methodology that could address multimorbidity within a single economic model by linking multiple single-disease models and, therefore, demonstrate the feasibility of using published models to incorporate multiple conditions within a single model. The method was illustrated using a case study of 3 selected diseases. The article is now presented in 3 main sections. The next section describes the linkage methods used and the relevant case study. The third section reports the base-case results from the linked models, including a key finding associated with interpretation of results. The fourth section discusses the implications and limitations of using this approach in practice.
Methods
This study demonstrates a method for linking multiple single-disease economic models using a discrete event simulation (DES) constructed in SIMUL8 (SIMUL8 Corporation). Three approaches to conceptualizing and constructing an economic model were directly compared: 1) aggregating results from multiple single-disease models, 2) modeling multiple diseases simultaneously within a single economic model, and 3) incorporating correlations between diseases in the multidisease economic model created in (2) .
A case study was used to illustrate the methods. Multimorbidity was captured in the case study using 3 example diseases: heart disease (HD), Alzheimer's disease (AD), and osteoporosis. Three diseases were selected to demonstrate the ability of the method to address any number of diseases that may co-occur. The selection of the relevant diseases to include in the case study was based on the economic, mortality, and morbidity burden of each condition and the desire to cover a spectrum of conditions (see Supplementary Appendix 1 for detailed selection criteria). A reference economic model to inform decisions on the structure, sources of data, and key assumptions for each disease was identified from a rapid review of recently published economic models. [19] [20] [21] Using these economic models, the current recommended treatments for the 3 diseases (statins for HD, donepezil for mild to moderate AD and memantine for severe AD, and alendronic acid for osteoporosis) were compared with no drug treatment. The specific details of the case study and challenges associated with the application of the method are reported in Supplementary Appendices 1 to 8.
The analysis was undertaken from the perspective of UK National Health Service (NHS) and Personal Social Services in line with the reference case stipulated by NICE. 22 A lifetime horizon was used to fully assess the long-term effect of the interventions. Costs and health outcomes associated with a lifetime use of the interventions were presented in terms of pounds sterling (£ in 2012/2013 price) and QALYs, respectively. The relevant population was defined as the UK general population aged 45 years and older with or without the diseases, rather than only the elderly, to fully capture the prevention effect of the interventions. Age and gender values were randomly sampled from the UK mid-2012 population estimates. 23 Those individuals who did not have the disease may or may not develop it before death based on the age-and gender-stratified incidence of the disease. A discount rate of 3.5% per annum was used for both costs and QALYs. The next section describes the methods used to link multiple single-disease models in reference to the conventional DES approach.
Individual Patient Modeling Methods
A DES approach was chosen for modeling the 3 diseases in which individual patients are simulated to move through different disease events sampled from time-toevent distributions. The selected diseases were modeled individually and then combined within a single DES model as a linked-disease economic model (see Figure 1 ). Potential correlations between the diseases were additionally explored in the linked-disease economic model. Figure 2 illustrates the method for model linkage with respect to simulation time.
Individual patient modeling was used to provide more flexibility to incorporate heterogeneity among patients when compared with cohort modeling. Although cohortbased models can theoretically account for different characteristics of individuals such as age, risk factors, and history of other diseases, the number of dimensions needed for the relevant health states become exponentially large. 24 The time-to-event approach used in DES provided a practical option for linking multiple diseases. Transition probabilities for prespecified equal-length cycles as in state-transition cohort (Markov) models are not required, allowing for greater flexibility during times when events can occur. DES models can also record more individual attributes to account for patient history than Markov models: the rate of event 1, r(Event 1), is updated once an individual experiences event 2, such that r(Event 1jEvent 2) 6 ¼ r(Event 1). Figure 2a represents an economic model for a disease shown as a course of changes over time in ''variables'' that define the modeled system (the process of disease progression). Figure 2a -ii depicts a Markov model in the same format as the DES model for a selected individual from a cohort. Any occurrences that alter any set of such variables can be considered as ''events.'' The variables describing the state of a disease process at a point in time include global variables that apply to all simulated individuals (e.g., discount rates and unit costs of interventions) and individual attributes that may or may not change over time (e.g., age, sex, and individual's disease history or changes in state membership if an individual from a Markov cohort is considered). The model outcomes such as lifetime costs and QALYs are based on the trajectories of these variables. Figure 2a shows how the DES allows for changes in the system variables to occur at any discrete point in time such that multiple events can occur within a short period of time. The calculation of costs and QALYs is then made only when events occur, not at every cycle as in Markov models, hence allowing a large number of disease events to be incorporated in DES models.
Modeling Methods for Linked Model: General Approach
The flexibility of the DES approach means that it is possible to merge existing single-disease economic models to create a linked-economic model by combining all eventdefining variables within 1 system (see Figure 2b ). In the linked economic models, costs were assumed to be additive. Four approaches (additive, minimum, multiplicative, and linear index methods) to combine utility values for joint health conditions are possible in the absence of actual data for a population with more than 1 health condition. There is no agreement on the best approach, and current recommendations suggest using the multiplicative method, which was the approach adopted in this study. 25 Individuals with multiple diseases may have a higher risk of death. Multimorbidity is taken into account for disease-related death as competing risks: HD-and fracture-related deaths. The earliest time to diseaserelated death was determined at the central router in the DES. Death may not be related to any of the diseases explicitly modeled. Nondisease mortality rates in the linked model were defined as all-cause mortality obtained from the UK Interim Life Tables 26 minus the death rates associated with the diseases included in the model.
Two versions of the linked-economic model were constructed, which assumed 1) independence between the 3 diseases or 2) correlation between the diseases. A probabilistic analysis was conducted using the linked economic model assuming correlation. The next section describes how the linked economic model assuming independence between the 3 diseases was constructed. Independence assumes that the presence of one disease does not affect the risk of the others (denoted hereafter as an ''independently linked model''). Competing risks across all individual disease models can also be compared, and individuals are directed to move to the event corresponding to the earliest scheduled time to event. This linked-economic model can provide a seamless approach, especially when populations at increased risks of multimorbidity are modeled and when existing models are available for the individual diseases. Table 1 provides additional details on the process used to update event times and routing. The table shows how to follow an individual through the DES from model entry. Individuals can have 0, 1, 2, or 3 of the diseases and enter the combined model with characteristics sampled at the entry point. These characteristics are used for the sampling of times to next event (TTNEs) and/or the calculation of aggregate costs and QALYs. Individuals enter the DES model through the central routing point where the transition to the next event is executed. Once the individuals move to the event and all relevant parameters are updated, they return to the central router to be routed to the next event. This process is repeated until an individual has been simulated up until the point at which they die. Recording the history of previous events means that the DES can account for multimorbidity, in terms of event costs, HRQoL, and influence on risks of future events. The times to all further predicted events are then either resampled based on updated parameters or reduced by the TTNE to account for the passing of time. For example, at the central routing point, TTNEs for the other diseases are subtracted by the time spent in the previous event. Other timerelated variables, such as time before the effect of treatments stops and time before the end of the first year of any cardiac events or osteoporotic fractures, are then recalculated.
Linked economic model: assuming correlations between diseases. This section describes how the correlation between the 3 diseases was taken into account in the linked economic model. Incorporating correlations between diseases assumes that having one disease can affect the risk of other diseases, and hence, correlations between diseases are incorporated (denoted hereafter as ''correlated linked economic model''). The correlated linked economic model assigns disease history and event .... The process continues until death *For illustration, the same utility values were assumed across all events within one disease: 0.7 for heart disease events and 0.8 for osteoporosis events. A constant baseline utility weight of 0.85 was assumed; y When the same event occurs more than once (e.g. two strokes within a year), a utility multiplier is applied only once.
probabilities based on the status of the other diseases included in the DES model. Correlations associated with prevalence were incorporated to set the distribution of diseases at the start of the model, and correlations associated with incidence were used to dynamically change the incidence of one disease conditional on the occurrence of other disease events.
The model assumed that the occurrence of HD events affects the incidence of AD but not vice versa because of the relatively later onset of AD compared with that of HD. 27 There is growing evidence that supports the idea that osteoporosis is correlated with both HD and AD, as greater vascular dysfunction is associated with lower bone mineral density. [28] [29] [30] Excess fracture risk has been reported among patients with a diagnosis of myocardial infarction with a hazard ratio of 1.73 (95% confidence interval, 1.32-2.27). 31 The DES assumed that a history of HD events would increase fracture risks and those with previous fracture would be at an increased risk of stroke and AD onset. 31, 32 For demonstrating a proof-of-concept model, correlations regarding selected prevalence and incidence estimates were deemed sufficient. Five types of correlations (see Supplementary Appendix 2 for details) were incorporated in the correlated linked model: 1) prevalence and 2) incidence of AD in people with and without HD; 3) incidence of hip fracture for people with a history of myocardial infarction; 4) the risk of stroke among people with a history of hip fracture; and 5) the incidence of AD in people with low bone mineral density. Correlations associated with prevalence were incorporated at the start of the model by setting the distribution of diseases across individuals. Correlations associated with incidence were incorporated using a more dynamic approach. For example, after an individual develops an HD event, the incidence of AD for that individual was changed from the time of that HD event. To incorporate the correlation between AD and HD, the total proportion of people who have AD was divided into the proportion of AD patients among people with HD and the proportion among people without HD. The incidence of AD for the total population was divided into that for the population with HD and for the population without HD, such that the sum of the incidence values equals the total incidence.
Constructing Single-Disease Models
This section describes how the 3 single-disease economic models (HD, AD, and osteoporosis) were conceptualized and built for the case study (see Figure 3 ). A rapid review was undertaken to identify economic models published as part of the UK National Institute for Health Research Health Technology Assessment monograph series (https:// www.journalslibrary.nihr.ac.uk/HTA/). Two of the 3 identified relevant single-disease models were Markov cohort models (HD and AD). The core structure of each identified economic model for each single disease was maintained but adapted to be implemented on a DES platform. Data sources reported in the published health technology assessment (HTA) reports were also used as model input parameters (see Supplementary Appendix 3 ). All transition probabilities reported in the published economic models were converted to rates. Event rates reflect the instantaneous likelihood of the event occurring per unit of time. For each model, the appropriate number of simulated individuals to ensure stable outcomes was identified by examining the standard error of the mean estimates of (incremental) cost and QALYs, and the mean and jackknife confidence interval for the incremental cost per QALY estimate. 33 The results from the 3 single-disease models were compared with those of the published models to externally validate the model.
HD model. The state transition cohort model developed by Ward et al., 19 and used to inform guidance recommended by NICE, was used as the single disease model for HD (Figure 3a) . Statins, assuming a common class effect, were the intervention used for the secondary prevention of HD in patients with angina, myocardial infarction, peripheral artery disease (PAD), or a history of stroke and for primary prevention in patients who are at increased risk of coronary events. High-risk patients were defined as those whose estimated 10-year risk of developing cardiovascular disease is greater than 20% according to NICE TA94 19 : however, the threshold was amended to 10% in 2014. 34 Sources of data and key assumptions reported in Ward et al. 19 were considered as the main reference for the model. A review of existing models suggested that the single-disease economic model for HD should be adapted to include PAD and that it was necessary to update some parameter estimates (see Supplementary  Appendix 3 ).
First-year events and events in subsequent years were kept distinct because of the differences in the cost of interventions and HRQoL within these time periods. No difference in event rates was assumed between the first year and subsequent years after PAD because there was no clinical evidence identified distinguishing the 2 periods. The DES uses continuous time, which means it was possible for an individual to have multiple events and associated utility values within a 12-month period. It was therefore possible for 1 individual to incur 2 or more utility modifiers associated with first-year events. An event updating utility values was added to the model to ensure that changes in HRQoL were handled appropriately.
Alzheimer's disease. A DES model for AD was constructed ( Figure 3b ) based on the Markov model published in the HTA report by Bond et al. 20 After a diagnosis of AD, the model structure replicated the 3state model in Bond et al. 20 In line with the current NICE recommendation, 35 it was assumed that patients with a Mini-Mental State Examination (MMSE) score between 10 and 26 at diagnosis (i.e., 10 MMSE 26) received donepezil. Memantine was assumed for patients with MMSE \ 10.
A simulated population representative of the UK population aged 45 and older was assumed to enter the model. This analysis assumed that some individuals have AD when entering the model. Those entering the model without AD may or may not develop AD before death based on the sampled time to onset of AD. It was assumed that diagnosis of AD is not instantaneous, as the development of symptoms is gradual.
Osteoporosis model. The economic model produced by Stevenson et al. 21 was used as a basis for the osteoporosis model constructed for the case study (see Figure 3c ).
Events included in the DES model for osteoporosis were defined by 4 index fracture sites (hip, vertebral, wrist, and proximal humerus fractures) and the risks of nursing home entry from hip fracture, death following fracture, and non-fracture-related death. The events representing initiation and discontinuation of a preventative pharmacologic intervention (70 mg alendronate taken once weekly) were also included. The model included fractures occurring to both osteoporotic and nonosteoporotic populations. 21 It was possible to have 2 first-year utility multipliers acting simultaneously. An event to update utility values was included in the model to reflect that utilities for the first year and subsequent years after a fracture could be different.
Results
This section presents illustrative simulation results for the UK general population aged 45 years and older from the case study. The 3 single-disease models produced results comparable with those from the published reference models despite the difference in model populations (see Supplementary Appendix 4) . Results are reported from 2 types of linked models: those from the independently linked model, followed by those from the correlated linked Table 2 reports the base-case results from the linked economic model assuming independence between the 3 diseases. Incremental cost-per-QALY estimates for the 3 interventions (statins, donepezil or memantine, alendronate) for the 3 diseases in combination (HD, AD, osteoporosis, respectively) differed between the linked economic model and the individual disease DES models. There were higher incremental costs (£840) and lower incremental QALYs (0.234) in the linked economic model compared with the sum of the 3 single-disease model results (£408, 0.280; see Supplementary Appendix 6). The absolute costs from the independently linked model (£14,776 for intervention arm) were slightly lower than the sum of the absolute costs from the 3 single-disease models (£15,520). The absolute QALYs (8.956 for intervention arm) were also lower than the minimum of the equivalent values from the 3 individual disease models (9.249), as utility levels were generally lower in the model including multiple diseases than in the models that consider only 1 disease. Table 3 presents incremental cost and QALYs as well as cost per QALY estimates of each intervention (statins, donepezil or memantine, alendronate) from the independently linked model based on 700,000 simulated individuals. This analysis assumed that the interventions for the other 2 conditions were available to individuals. The results differed from the results from the single-disease models: the linked model produced larger incremental costs and smaller incremental QALYs in absolute values than the single-disease models (see Supplementary Appendix 6) .
Linked Economic Model: Assuming Independence
This difference was most noticeable for the AD intervention, which produced lower QALYs with lower costs than no treatment in the linked model (incremental QALYs of -0.001; incremental cost of -£24), whereas it was dominating no treatment in the individual AD model (Supplementary Appendix 6) . The results shown in Table  3 did not have face validity because it was not considered plausible to have negative incremental QALYs associated with an AD intervention: donepezil or memantine only delays cognitive impairment, and the model did not capture the impact of adverse drug events. Therefore, the number of simulated individuals was increased to 2 million from 700,000 individuals, and then face validity improved, with the AD intervention dominating no treatment with a very small QALY gain. The small incremental values were in line with the results from the Bond et al. study. 20, 36 Impact of imbalance between the linked diseases on the interpretation of the results. Making a direct comparison between the absolute size of incremental QALYs and costs per person across the single-disease economic models (Figure 4 ; Supplementary Appendix 6), it is clear that the effect of the HD intervention was much larger than those interventions for AD or osteoporosis. The results were shown to be stable within individual disease models. The relative cost-effectiveness of individual interventions estimated from the linked economic model could potentially be affected by the level of balance between the size of QALYs and cost outcomes from the individual diseases included in the linked economic model (regardless of whether independence or correlation was assumed). This effect was observed when the QALY gains from one disease (in the case study, HD) were much larger than those for the remainder, and there were different levels of Monte Carlo sampling error between diseases. Hence, an acceptable level of sampling error in one disease for robust adoption decision for that disease could significantly impact the QALYs and cost outcomes for the other diseases. The margin of error, defined as the half width of the 95% confidence interval in this study, around the mean incremental QALYs, was used to describe the amount of random sampling error in the simulation results. 37 In the individual HD model, the margin of error was estimated to be 0.0288 QALYs based on 200,000 simulated individuals. To estimate the predicted margin of error of the mean incremental QALYs with increased number of simulated individuals (N), a power regression model was used to fit a nonlinear curve that decreases proportionally by ffiffiffiffi N p (R 2 = 0.9999). Using the fitted equation, the margin of error in incremental QALYs for the HD intervention with 700,000 individuals was predicted to be 0.0155 QALYs. With 10 million individuals simulated, this value (0.0042 QALYs) was still large compared with the incremental QALYs associated with the interventions for AD (0.001 QALYs) and osteoporosis (0.008 QALYs). This shows that, where the treatment of one disease has a much larger absolute impact on cost and QALYs than the impact of treatments for the other disease, a very large number of individuals may need to be simulated for stable results to be achieved in a linked model. Supplementary Appendix 7 describes a hypothetical scenario in which a similar level of QALY gains was assumed for all 3 interventions, and the adoption decision within the linked model for each individual intervention was robust. Table 4 reports the base-case results from the linked economic model incorporating the correlations. The incremental cost-per-QALY results for the combination of the 3 interventions were similar to the results from the independently linked model (£3,583 per QALY gained). When the 3 diseases were assumed to be correlated, the absolute values of QALYs and life-years increased, and costs were lower. This was the result of positive correlations between diseases, resulting in multimorbidity being more concentrated within a narrower population. Table 5 shows the results of running the model with 2 million individuals simulated to reduce the impact of the aforementioned sampling error issue. A probabilistic sensitivity analysis (PSA) using the correlated linked model was undertaken, and its feasibility in the multidisease DES context is discussed in Supplementary Appendix 8. All of the 300 PSA samples showed incremental cost-per-QALY being lower than the threshold of £20,000 per QALY gained (Supplementary Figure S8.1, Supplementary Appendix 8) . Conducting 300 PSA runs required 1.9 days of computing time for each intervention arm (Intel Core i7CPU 3.40-GHz processor with 16 GB RAM).
Linked Economic Model: Assuming Correlation between Diseases

Discussion
This study aimed to demonstrate a proof-of-concept method to link multiple single-disease models using a case study involving 3 diseases (HD, AD, and osteoporosis) managed with 3 interventions (statins, donepezil or memantine, alendronate). The inclusion of multiple diseases in a single DES model also enabled correlation between the diseases to be incorporated. This illustrative example showed that producing a linked economic model was feasible using DES and also allowed a PSA to be performed. The results from the 3 single-disease models were broadly comparable with those from the published economic models despite differences in model populations, costs, and health events included ( Supplementary  Appendix 4) . The linked economic model results showed that incorporating multiple diseases and correlations between them in a model can produce different estimates of aggregate costs and QALYs for a disease when compared with those estimates derived from single-disease models. In general, the magnitude of the difference between single-and linked-model results increased with the proportion of the model population developing multiple diseases. These results confirm a priori expectations that when considering a population of individuals who are susceptible to multiple health conditions, producing an economic model that focuses on a single disease will not only misrepresent actual care pathways but seriously bias the estimated costs and QALYs. Consequently, an intervention could be mistakenly estimated to be costeffective when it is not. This potential for bias is relevant in the context of both allocation of health care resources and clinical guidelines. An economic model that appropriately links multiple diseases is likely to produce different decisions on technology adoption, which in turn could alter the nature of the NHS-funded treatment options made available in clinical practice. 38, 39 To be able to appropriately measure the impact of multimorbidity, it is necessary to carefully select the relevant coexisting diseases for a specified decision problem. Ideally, the use of predefined criteria (as exemplified in Supplementary Appendix 1) should be used to guide the selection of relevant diseases. Careful consideration should be paid to how many of the relevant diseases should be included in a linked economic model. The same principles used for single-disease modeling also apply to the selection of multiple diseases: the diseases considered to alter model outcomes that are important for the population being studied and to policy makers (such as costs and QALYs) should be included. Epidemiological data that identify commonly coexisting health conditions (for example, see ref. 10) can be used to inform the choice of which diseases are most relevant. The assessment of marginal returns to adding more diseases in the linked model could be investigated empirically.
This proof-of-concept analysis suggested that when one disease had a much larger impact on costs and QALYs than the other diseases in a linked economic model, the sampling error around the disease with larger impact could make a significant difference to the estimated costeffectiveness of the other individual treatments. This result could lead to lack of face validity for the diseases with smaller incremental gains. The implication is that the number of simulated patients required to stabilize the adoption decisions within linked economic models may be greater than the maximum of the numbers required for singledisease models. In circumstances in which the QALY gains are similar across individual treatments, it is likely that the proposed methods of linking single-disease models produce more accurate estimates for multimorbid populations. Further research on approaches to addressing this problem, in particular when incremental costs and QALYs are small in magnitude, would be beneficial.
The analysis showed that including correlations between diseases may potentially change the relative cost-effectiveness of interventions. When correlations were implemented, absolute QALYs were higher than when the diseases were assumed independent because of the concentration of comorbidities onto an already diseased population, resulting in lower QALY loss from having an additional disease. Hence, adding correlations better reflects the relationship between multimorbidity and mortality. This article demonstrated how to include correlations, based on the currently available data.
Further evidence on correlations between diseases may become available in the future, which would allow the model to be extended and improved.
The DES approach, as illustrated in this article, showed how it was sufficiently flexible to allow the impact of different types of individuals in a population to be quantified. The general population was used as the entry population in the DES model, but it is possible to define more specific populations with different distributions of individual characteristics, for example, a population of individuals with prevalent HD but without osteoporosis. In turn, a particular health intervention could be evaluated for these individuals in a population, which mirrors the approach in conventional HTA analyses for interventions in single diseases.
There were some limitations to this proof-of-concept method. The use of the DES framework enabled the seamless linkage of the 3 disease distinct economic models, but future work could explore the application of the linkage method using methods other than DES. Also, the multiplicative method was used to combine utility values for the co-occurring health conditions. There are 3 other possible methods: additive, minimum, and linear index methods. Each of these methods is likely to produce different utilities for any combination of health states, but the direction of the changes in the observed utility values will be the same. A future study could investigate the impact of using different methods to combine utility values on the magnitude of the cost-effectiveness of interventions in a linked model for more than one disease. 40 In this proof-of-concept study, time-to-event distributions and random numbers were used to represent the variability among individual observations (first-order uncertainty) as reported in Supplementary Appendix 5. Uncertainty around the structure of the economic model was not examined. A PSA is required to understand the impact of second-order uncertainty arising from uncertainty in the model input parameters. 41 A feasibility run of PSA was undertaken that showed a significant model running time would be required to conduct a large-scale PSA for this model (Supplementary Appendix 8) . A study designed to understand the impact of parameter and structural uncertainty in a linked economic model could be a topic for future research using parallel computing or expedited PSA with nonparametric regression modeling. 42 Also, running the model for a more narrowly defined population with specific characteristics and higher disease prevalence, rather than for the general population, would accelerate convergence to mean outcomes at each deterministic run.
In conclusion, this proof-of-concept study used DES to produce a linked economic model and demonstrated that this is a feasible approach to inform decision making relevant to interventions for populations with multimorbidity. This study provided a modeling framework that has the potential to be modified and/or expanded to incorporate other diseases and interventions to inform the development of clinical guidelines using evidence about the relative cost-effectiveness of interventions for people with multimorbidity. This study has shown that using a linked economic model that incorporates correlations between diseases is likely to influence the potential decisions made about the allocation of health care resources to support interventions relevant to multimorbid populations, increasing the health benefits experienced by those patients.
ORCID iD
Ji-Hee Youn https://orcid.org/0000-0003-1382-495X
Supplemental Material
Supplementary material for this article is available on the Medical Decision Making Web site at http://journals.sagepub .com/home/mdm.
